These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 29337986)

  • 1. The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors.
    Verma RK; Abramyan AM; Michino M; Free RB; Sibley DR; Javitch JA; Lane JR; Shi L
    PLoS Comput Biol; 2018 Jan; 14(1):e1005948. PubMed ID: 29337986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The structural determinants of the bitopic binding mode of a negative allosteric modulator of the dopamine D
    Draper-Joyce CJ; Michino M; Verma RK; Klein Herenbrink C; Shonberg J; Kopinathan A; Scammells PJ; Capuano B; Thal DM; Javitch JA; Christopoulos A; Shi L; Lane JR
    Biochem Pharmacol; 2018 Feb; 148():315-328. PubMed ID: 29325769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The action of a negative allosteric modulator at the dopamine D
    Draper-Joyce CJ; Verma RK; Michino M; Shonberg J; Kopinathan A; Klein Herenbrink C; Scammells PJ; Capuano B; Abramyan AM; Thal DM; Javitch JA; Christopoulos A; Shi L; Lane JR
    Sci Rep; 2018 Jan; 8(1):1208. PubMed ID: 29352161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity study of N-((trans)-4-(2-(7-cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-2-carboxamide (SB269652), a bitopic ligand that acts as a negative allosteric modulator of the dopamine D2 receptor.
    Shonberg J; Draper-Joyce C; Mistry SN; Christopoulos A; Scammells PJ; Lane JR; Capuano B
    J Med Chem; 2015 Jul; 58(13):5287-307. PubMed ID: 26052807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The First Negative Allosteric Modulator for Dopamine D
    Rossi M; Fasciani I; Marampon F; Maggio R; Scarselli M
    Mol Pharmacol; 2017 Jun; 91(6):586-594. PubMed ID: 28265019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single glycine in extracellular loop 1 is the critical determinant for pharmacological specificity of dopamine D2 and D3 receptors.
    Michino M; Donthamsetti P; Beuming T; Banala A; Duan L; Roux T; Han Y; Trinquet E; Newman AH; Javitch JA; Shi L
    Mol Pharmacol; 2013 Dec; 84(6):854-64. PubMed ID: 24061855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subtle Modifications to the Indole-2-carboxamide Motif of the Negative Allosteric Modulator N-(( trans)-4-(2-(7-Cyano-3,4-dihydroisoquinolin-2(1 H)-yl)ethyl)cyclohexyl)-1 H-indole-2-carboxamide (SB269652) Yield Dramatic Changes in Pharmacological Activity at the Dopamine D
    Kopinathan A; Draper-Joyce C; Szabo M; Christopoulos A; Scammells PJ; Lane JR; Capuano B
    J Med Chem; 2019 Jan; 62(1):371-377. PubMed ID: 29890071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular determinants of selectivity and efficacy at the dopamine D3 receptor.
    Newman AH; Beuming T; Banala AK; Donthamsetti P; Pongetti K; LaBounty A; Levy B; Cao J; Michino M; Luedtke RR; Javitch JA; Shi L
    J Med Chem; 2012 Aug; 55(15):6689-99. PubMed ID: 22632094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a Novel Class of Negative Allosteric Modulator of the Dopamine D2 Receptor Through Fragmentation of a Bitopic Ligand.
    Mistry SN; Shonberg J; Draper-Joyce CJ; Klein Herenbrink C; Michino M; Shi L; Christopoulos A; Capuano B; Scammells PJ; Lane JR
    J Med Chem; 2015 Sep; 58(17):6819-43. PubMed ID: 26258690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct inactive conformations of the dopamine D2 and D3 receptors correspond to different extents of inverse agonism.
    Lane JR; Abramyan AM; Adhikari P; Keen AC; Lee KH; Sanchez J; Verma RK; Lim HD; Yano H; Javitch JA; Shi L
    Elife; 2020 Jan; 9():. PubMed ID: 31985399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors Governing Selectivity of Dopamine Receptor Binding Compounds for D2R and D3R Subtypes.
    Hayatshahi HS; Luedtke RR; Taylor M; Chen PJ; Blass BE; Liu J
    J Chem Inf Model; 2021 Jun; 61(6):2829-2843. PubMed ID: 33988991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor.
    Adhikari P; Xie B; Semeano A; Bonifazi A; Battiti FO; Newman AH; Yano H; Shi L
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33924613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new mechanism of allostery in a G protein-coupled receptor dimer.
    Lane JR; Donthamsetti P; Shonberg J; Draper-Joyce CJ; Dentry S; Michino M; Shi L; López L; Scammells PJ; Capuano B; Sexton PM; Javitch JA; Christopoulos A
    Nat Chem Biol; 2014 Sep; 10(9):745-52. PubMed ID: 25108820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for a Stereoselective Mechanism for Bitopic Activity by Extended-Length Antagonists of the D
    Moritz AE; Bonifazi A; Guerrero AM; Kumar V; Free RB; Lane JR; Verma RK; Shi L; Newman AH; Sibley DR
    ACS Chem Neurosci; 2020 Oct; 11(20):3309-3320. PubMed ID: 32969645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinctive binding properties of the negative allosteric modulator, [
    Fasciani I; Pietrantoni I; Rossi M; Mannoury la Cour C; Aloisi G; Marampon F; Scarselli M; Millan MJ; Maggio R
    Eur J Pharmacol; 2018 Jan; 819():181-189. PubMed ID: 29223348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D
    Free RB; Cuoco CA; Xie B; Namkung Y; Prabhu VV; Willette BKA; Day MM; Sanchez-Soto M; Lane JR; Laporte SA; Shi L; Allen JE; Sibley DR
    Mol Pharmacol; 2021 Oct; 100(4):372-387. PubMed ID: 34353882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity.
    Ananthan S; Saini SK; Zhou G; Hobrath JV; Padmalayam I; Zhai L; Bostwick JR; Antonio T; Reith ME; McDowell S; Cho E; McAleer L; Taylor M; Luedtke RR
    J Med Chem; 2014 Aug; 57(16):7042-60. PubMed ID: 25126833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and evaluation of bitopic arylpiperazinephenyl-1,2,4-oxadiazoles as preferential dopamine D3 receptor ligands.
    Cao Y; Min C; Acharya S; Kim KM; Cheon SH
    Bioorg Med Chem; 2016 Jan; 24(2):191-200. PubMed ID: 26707842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity.
    Zou MF; Keck TM; Kumar V; Donthamsetti P; Michino M; Burzynski C; Schweppe C; Bonifazi A; Free RB; Sibley DR; Janowsky A; Shi L; Javitch JA; Newman AH
    J Med Chem; 2016 Apr; 59(7):2973-88. PubMed ID: 27035329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors.
    Lane JR; Chubukov P; Liu W; Canals M; Cherezov V; Abagyan R; Stevens RC; Katritch V
    Mol Pharmacol; 2013 Dec; 84(6):794-807. PubMed ID: 24021214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.